Lukas E. Dow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lukas E. Dow has a total of 564 co-authors. Here are the top co-authors by number of shared publications:
Miguel Foronda
Weill Cornell Medicine
46 shared publications- Scott W. Lowe
Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
46 shared publications Olivier Elemento
Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine
45 shared publications- Albrecht Neesse
Klinik für Gastroenterologie, gastrointestinale Onkologie und Endokrinologie, Universitätsmedizin Göttingen, Göttingen, Deutschland
43 shared publications - Anthony Evans
University of Liverpool
43 shared publications - Camino Bermejo-Rodriguez
Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
43 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in Nature Chemical Biology
A selective TNKS2 inhibitor for tumor-restricted WNT suppression
Hyperactive WNT signaling is a potent cancer driver but clinical translation of WNT inhibitors has been hampered by on-target toxicities. WNT signaling can be constrained through inhibition of the PARP-family enzymes tankyrase 1 (TNKS1) and TNKS2; however, existing TNKS inhibitors suppress WNT signaling in both tumor and healthy tissues. In this Article, we show that genomic loss of TNKS1 on chromosome 8p creates a collateral vulnerability that drives a tumor-restricted dependency on TNKS2 for cellular TNKS activity. Through structure-guided design, we identify a flexible loop in TNKS2 that can be exploited to enable TNKS2-selective drug targeting and we generate a first-in-class TNKS2 inhibitor to drive selective WNT inhibition in TNKS1-deficient cell and organoid models. This work demonstrates a targetable cancer-specific vulnerability in multiple cancer types, providing a new approach for WNT-targeted therapies.
- 2 November 2026
- Published by Springer Nature in Nature Chemical Biology
Open AccessA selective TNKS2 inhibitor for tumor-restricted WNT suppression
Hyperactive WNT signaling is a potent cancer driver but clinical translation of WNT inhibitors has been hampered by on-target toxicities. WNT signaling can be constrained through inhibition of the PARP-family enzymes tankyrase 1 (TNKS1) and TNKS2; however, existing TNKS inhibitors suppress WNT signaling in both tumor and healthy tissues. In this Article, we show that genomic loss of TNKS1 on chromosome 8p creates a collateral vulnerability that drives a tumor-restricted dependency on TNKS2 for cellular TNKS activity. Through structure-guided design, we identify a flexible loop in TNKS2 that can be exploited to enable TNKS2-selective drug targeting and we generate a first-in-class TNKS2 inhibitor to drive selective WNT inhibition in TNKS1-deficient cell and organoid models. This work demonstrates a targetable cancer-specific vulnerability in multiple cancer types, providing a new approach for WNT-targeted therapies.
- Open Access
- 10 September 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase
Table S1 shows Overlap of differential regulated genes in EZH2high vs EZH2low and EZH2i vs vehicle of EZH2high cells comparisons identifies 12 common genes.
- 10 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase
Table S1 shows Overlap of differential regulated genes in EZH2high vs EZH2low and EZH2i vs vehicle of EZH2high cells comparisons identifies 12 common genes.
- Open Access
- 10 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S10 from Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase
Supplementary Figure S1 shows correlation of EZH2 gene expression with FGA in METABRIC and TCGA breast cancer cohort suggests a link between EZH2 and CIN. Supplementary Figure S2 shows correlation between fraction genome altered (FGA) and EZH2 gene expression in TCGA LUAD cohort. Supplementary Figure S3 shows increased CIN in various TNBC, non-TNBC and and RPE1 cells and impact of EZH2 inhibition. Supplementary Figure S4 shows EZH2 inhibition and cell cycle analysis. Supplementary Figure S5 shows CUT & RUN seq and RNA-seq analysis. Supplementary Figure S6 shows visualization and experimental validation of EZH2 target genes. Supplementary Figure S7 shows EZH2 mediated TNKS regulates CIN. Supplementary Figure S8 shows multipolar mitosis and supernumerary centrosome analysis of the TNKS KO cells. Supplementary Figure S9 shows correlation of EZH2, CPAP and aneuploidy and effect of EZH2 inhibition on CPAP expression and cell cycle analysis of TNKSWT and TNKSKO LM2 cells. Supplementary Figure S10 shows impact of CIN modulation on proliferation and metastatic progression in EZH2 WT and EZH2 KO cells.
- 10 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S10 from Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase
Supplementary Figure S1 shows correlation of EZH2 gene expression with FGA in METABRIC and TCGA breast cancer cohort suggests a link between EZH2 and CIN. Supplementary Figure S2 shows correlation between fraction genome altered (FGA) and EZH2 gene expression in TCGA LUAD cohort. Supplementary Figure S3 shows increased CIN in various TNBC, non-TNBC and and RPE1 cells and impact of EZH2 inhibition. Supplementary Figure S4 shows EZH2 inhibition and cell cycle analysis. Supplementary Figure S5 shows CUT & RUN seq and RNA-seq analysis. Supplementary Figure S6 shows visualization and experimental validation of EZH2 target genes. Supplementary Figure S7 shows EZH2 mediated TNKS regulates CIN. Supplementary Figure S8 shows multipolar mitosis and supernumerary centrosome analysis of the TNKS KO cells. Supplementary Figure S9 shows correlation of EZH2, CPAP and aneuploidy and effect of EZH2 inhibition on CPAP expression and cell cycle analysis of TNKSWT and TNKSKO LM2 cells. Supplementary Figure S10 shows impact of CIN modulation on proliferation and metastatic progression in EZH2 WT and EZH2 KO cells.
- Open Access
- 10 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Materials 1 from Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase
Supplementary materials include materials and methods, supplementary Figure S1 to S10, figure legends and references.
- 10 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials 1 from Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase
Supplementary materials include materials and methods, supplementary Figure S1 to S10, figure legends and references.
- Open Access
- 20 August 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (10) , 1715-1730
Role of orphan G protein-coupled receptor GPR52 in breast cancer cell multicellular organization and collective invasion
Background G protein-coupled receptors (GPCRs) are the largest class of membrane-bound receptors and are emerging as targets for the effective treatment of cancer. The role of orphan GPCR GPR52 in cancer has not been characterized. Low mRNA expression of GPR52 in breast tumours correlates with reduced overall survival, leading to the hypothesis that loss of GPR52 supports breast cancer progression. Methods CRISPR-Cas9 was used to knock out GPR52 in the human triple-negative breast cancer cell lines MDA-MB-468 and MDA-MB-231. 2D and 3D in vitro studies, electron microscopy, and a zebrafish xenograft model were used to assess the morphology and behaviour of GPR52 KO cells. Results Loss of GPR52 was associated with elevated levels of cAMP, increased cell–cell interaction in 2D cultures, more spindle-like morphology on collagen, altered 3D spheroid morphology, and increased propensity to organize and invade collectively. Zebrafish injected with GPR52 KO cells developed a greater total cancer area than control. RNA sequencing and proteomic analyses of GPR52-null cells revealed an increased cAMP signalling signature. Re-expression of GPR52 and inhibition of cAMP production rescued some GPR52 KO phenotypes. Conclusions GPR52 loss is a potential mechanism by which breast cancer progression may occur and supports the investigation of GPR52 agonism as a therapeutic option for breast cancer. Statement of Significance Loss of the orphan GPCR GPR52 in human breast cell lines leads to increased cell clustering, hybrid/partial EMT, and increased tumour burden in zebrafish, further expanding our understanding of mechanisms driving cancer progression and opening the door to novel therapeutic approaches.
- 20 August 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 135 (10) , 1715-1730
Open AccessRole of orphan G protein-coupled receptor GPR52 in breast cancer cell multicellular organization and collective invasion
Background G protein-coupled receptors (GPCRs) are the largest class of membrane-bound receptors and are emerging as targets for the effective treatment of cancer. The role of orphan GPCR GPR52 in cancer has not been characterized. Low mRNA expression of GPR52 in breast tumours correlates with reduced overall survival, leading to the hypothesis that loss of GPR52 supports breast cancer progression. Methods CRISPR-Cas9 was used to knock out GPR52 in the human triple-negative breast cancer cell lines MDA-MB-468 and MDA-MB-231. 2D and 3D in vitro studies, electron microscopy, and a zebrafish xenograft model were used to assess the morphology and behaviour of GPR52 KO cells. Results Loss of GPR52 was associated with elevated levels of cAMP, increased cell–cell interaction in 2D cultures, more spindle-like morphology on collagen, altered 3D spheroid morphology, and increased propensity to organize and invade collectively. Zebrafish injected with GPR52 KO cells developed a greater total cancer area than control. RNA sequencing and proteomic analyses of GPR52-null cells revealed an increased cAMP signalling signature. Re-expression of GPR52 and inhibition of cAMP production rescued some GPR52 KO phenotypes. Conclusions GPR52 loss is a potential mechanism by which breast cancer progression may occur and supports the investigation of GPR52 agonism as a therapeutic option for breast cancer. Statement of Significance Loss of the orphan GPCR GPR52 in human breast cell lines leads to increased cell clustering, hybrid/partial EMT, and increased tumour burden in zebrafish, further expanding our understanding of mechanisms driving cancer progression and opening the door to novel therapeutic approaches.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Scribble Deficiency Promotes Pancreatic Ductal Adenocarcinoma Development and Metastasis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
List of inhibitors tested in HTDS alone or in combination with gefitinib.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition
List of inhibitors tested in HTDS alone or in combination with gefitinib.